Poll Results

Which type of project(s) could you or your organization most benefit from in 2023?

In July 2022, the FDA proposed expanding the NDC to a uniform 12 numeric digit format to accommodate future needs when all options using the current formats have been exhausted. Alternative options shared by the industry have asked the FDA to consider retaining the current NDC formats and allow the use of alpha characters when all numeric options have been exhausted.

Which of the following transition types is your organization prepared for in the next 5 years?

What information would you most like to gain from an Online Listening Assessment for a particular drug therapy or device? (Multiple selections allowed)

Prescribing & Dispensing Concerns: 25%

Competitor Comparisons: 25%

Prescribing Information Alignment: 17%

Coverage & Reimbursement: 17%

Patient Affordability: 8%

Misinformation: 8%

Disease State Concerns: 0%

Do you feel like your organization understands the FDA’s Draft Guidance for Industry on Drug Importation?

We have reviewed the guidance and are taking a watch and wait approach: 75%

We have reviewed the guidance and are taking proactive steps to act on it: 25%

We have reviewed the guidance but do not feel like it will impact our organization: 0%

Not familiar/We have not reviewed the guidance: 0%

How will payers manage reimbursement of multiple interchangeable biosimilars?

MAC reimbursement: 10%

Generic non-MAC reimbursement rate: 10%

Brand reimbursement rate: 40%

Specialty drug specific rate: 40%

Average Sales Price (ASP): 0%

Average Manufacturer Price (AMP): 0%

National Average Drug Acquisition Cost (NADAC): 0%

In which area could you or your company most benefit from additional training?

Biosimilars and interchangeability requirements: 46.1%

Dynamics that drive PBM and health plan decisions: 15.4%

Various hurdles a prescription must clear before being dispensed: 15.4%

Changing 340B landscape: 15.4%

Flow of funds and prescriptions through the pharmacy channels: 7.7%

Pharmacy chain initiatives and strategy updates: 0%

In the next 5 years, what outcome is most likely for FDA management of accelerated approvals with subsequent failed confirmatory trials?

Status quo with extended review timelines and limited FDA authority: 64%

Legislative change leading to additional FDA authority and actions: 27%

Increased pharmaceutical manufacturer voluntary actions: 9%

Which drug will change from prescription to OTC first?

Naloxone: 60%

Statins: 0%

Oral Contraceptives: 30%

Influenza Antivirals: 0%

None of the Above: 10%

Which medical condition will benefit the most from digital therapeutics?

ADHD: 0%

Behavior and Mental Health: 62.5%

Diabetes: 25%

Gastrointestinal: 0%

Genitourinary: 0%

Musculoskeletal: 0%

Sleep: 0%

Substance Use Disorder: 0%

Wellness: 12.5%

Other: 0%

How soon will COVID-19 vaccines transition from government funded to commercially available?

Before the end of 2022: 12.5%

First half of 2023: 25%

Second half of 2023: 50%

2024 and beyond: 12.5%